1. Announcing a new member of the CSG editorial base: Helen Scott

We are delighted to announce that the CSG now has an Administrative Assistant: Helen Scott. Helen has been employed to help with the extra administration created by the CSG’s new programme grant for systematic reviews on diagnosis and staging of skin cancer, but she will assist with many different aspects of the editorial process.

Helen has returned to work after a career break having a family. She has a variety of administrative experience, having worked for the rail industry and in an MP’s office. She will work Monday to Wednesday (8.45am – 2.15pm), and she will be contactable on csg@nottingham.ac.uk.

2. Skin Surgery: An Evidence Based Update Meeting – 7 May 2015

Bookings are now open for the CEBD’s event on skin surgery on Thursday May 7th 2015.

This update will focus on underpinning surgical treatment of skin disease (mainly skin cancer) with the latest evidence from randomised controlled trials.

Further information about this event is on the UK Dermatology Clinical Trials Network website here: http://ukdctn.org/meetings/evidence/

You can reserve your place online now by following this link: http://store.nottingham.ac.uk/browse/extra_info.asp?compid=1&modid=2&catid=91&prodid=477
3. Harmonising Outcome Measures for Eczema (HOME) IV meeting

The next meeting of the Harmonising Outcomes for Eczema (HOME) initiative (www.homeforeczema.org) takes place from 09:00 on 23rd April to 16:00 on 24th April 2015 in Malmö Sweden (HOME IV). The meeting is free of charge and open to anyone with an interest in outcome measures for eczema. The focus will be on instruments for patient reported outcomes (symptoms and quality of life) and establishing how long-term control of eczema should be defined and measured. Click here for the draft programme or to register.

There is a supplementary patient session on the afternoon prior to the meeting (22nd April, 1400-1700) to provide patients with an opportunity to find out more about HOME and to ask questions about the data to be presented during the meeting.

Further to the consensus at HOME III that EASI is the preferred core instrument to measure clinical signs in all atopic eczema trials, guidance is now available on the HOME website on using EASI.